Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians

Clin Respir J. 2018 Apr;12(4):1767-1768. doi: 10.1111/crj.12677. Epub 2017 Aug 4.

Authors

Rosaria Casciaro¹, Stefano Costa², Patricia Dang³, Fabio Majo⁴, Mirco Ros⁵

Affiliations

¹ IRCCS G. Gaslini Institute, Via Gerolamo Gaslini, Genova, Italy.
² Gaetano Martino Hospital, Via Consolare Valeria, Messina, Italy.
³ Vertex Pharmaceuticals, Via Leonida Bissolati, Rome, Italy.
⁴ IRCCS Bambino Gesù Children's Hospital, Piazza di Sant'Onofrio, Rome, Italy.
⁵ Ca' Foncello Hospital, Piazzale dell'Ospedale, Treviso, Italy.

PMID: 28759146
DOI: 10.1111/crj.12677

No abstract available

Publication types

Letter

MeSH terms

Aminophenols / administration & dosage
Aminophenols / therapeutic use*
Aminopyridines / administration & dosage
Aminopyridines / therapeutic use*
Benzodioxoles / administration & dosage
Benzodioxoles / therapeutic use*
Chloride Channel Agonists / therapeutic use
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / genetics
Cystic Fibrosis Transmembrane Conductance Regulator / therapeutic use
Disease Progression
Drug Combinations
Drug Therapy, Combination
Forced Expiratory Volume / drug effects
Homozygote
Humans
Italy / epidemiology
Mutation
Quinolones / administration & dosage
Quinolones / therapeutic use*
Surveys and Questionnaires
Treatment Outcome

Substances

Aminophenols
Aminopyridines
Benzodioxoles
Chloride Channel Agonists
Drug Combinations
Quinolones
lumacaftor, ivacaftor drug combination
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
lumacaftor